Tuesday, November 17, 2026
4.8 C
London

Lilly’s New Amylin Drug Plus Zepbound: Up to 23% Weight Loss, But More Side Effects

Eli Lilly is testing a new experimental drug that may boost weight loss when combined with its existing treatment, Zepbound. Early results show participants lost up to 23% of their body weight.

The drug belongs to a class called amylin, which mimics a hormone that helps regulate appetite and blood sugar. It works differently from GLP-1 drugs like Zepbound.

In the trial, patients received both treatments together. The combination produced greater weight loss than Zepbound alone.

However, more side effects occurred in the combination group. These included nausea, vomiting, and diarrhea, which are common with weight-loss drugs.

Lilly is developing the amylin drug to treat both obesity and diabetes. The company aims to offer an alternative for patients who do not respond well to GLP-1 therapies.

Amylin drugs are not yet approved for weight loss. Several companies are racing to bring similar treatments to market.

The findings suggest combination therapy could become a future option. But researchers must balance added benefits against tolerability.

Lilly has not announced when it will seek regulatory approval. Further trials will determine the drug’s safety and effectiveness.

Hot this week

Pilots Maintained Contact With Air Traffic Controllers Throughout Nationwide Flight Departure Halt

Pilots largely stayed in contact with air traffic controllers...

2026 Midterms: Democrats Gained, but Progressive Candidates Lagged Behind

Democrats gained ground in the 2026 midterms, but progressive...

Dr. John H. Powers III Takes Helm of NIAID: A New Era in Infectious Disease Leadership

Dr. John H. Powers III will lead the National...

Supreme Court Blocks Trump Administration’s University of California Research Funding Cuts

The Supreme Court declined to let the Trump administration...

Micron, AMD and AI Chip Stocks Slide as Sector Selloff Deepens Ahead of Nvidia Earnings

Semiconductor stocks slid sharply as a broad selloff swept...

Topics

2026 Midterms: Democrats Gained, but Progressive Candidates Lagged Behind

Democrats gained ground in the 2026 midterms, but progressive...

Micron, AMD and AI Chip Stocks Slide as Sector Selloff Deepens Ahead of Nvidia Earnings

Semiconductor stocks slid sharply as a broad selloff swept...

Bond-Market Volatility Is Surging: Why It May Be the New Normal for Investors

Bond-market volatility is rising sharply, and investors may need...

Just 400 US Data Centers Now Outpace Michigan’s Entire Power Use

A Harvard study has found that just 400 US...

Nvidia After Jensen Huang: What Comes Next?

Nvidia CEO Jensen Huang has left the company following...
spot_img

Related Articles

Popular Categories

spot_imgspot_img